Literature Monitoring in Pharmacovigilance
The published scientific and medical literature is one of the sources a marketing-authorisation holder is legally obliged to monitor for information about the safety of its products — a case report in a journal describing an adverse reaction can be a valid individual case safety report (ICSR) and can be the first sign of a signal. Literature monitoring is the systematic, documented process of searching that literature, identifying relevant articles, and extracting reportable cases and safety information. It is a defined pharmacovigilance obligation with real structure, not an occasional scan. This page covers how it works; the cases it produces feed the [ICSR & expedited reporting](/topics/icsr-expedited-reporting) and [signal management](/topics/signal-management) explainers.
What an explainer is not
A topic explainer is SPEQ’s synthesis of what a practice involves, cited to the standards that govern it. It does not reproduce their text, and it does not determine which of them apply to your product or process.
[ POSITION IN THE FRAMEWORK ]
7 DIMENSIONS · 19 LINKSThe published literature is a legally mandated pharmacovigilance safety source: a systematic, documented, often weekly search whose ICSRs feed expedited reporting — with scope defined against the EMA MLM service.
06 · QUALITY MATURITY — LITERATURE MONITORING IN PHARMACOVIGILANCE, REACTIVE TO ADAPTIVE
Literature is scanned occasionally with no defined strategy; a published serious case can be missed for weeks.
A literature SOP names databases, but search frequency lapses and the MLM boundary is not mapped.
Specified databases are searched on a defined cadence with a documented strategy and an auditable article-to-case trail.
Search performance and vendor output are monitored; MLM coverage is kept current so no substance is unwatched or double-reported.
Literature monitoring is an integrated safety-surveillance input feeding signal detection, with scope continuously tuned to the portfolio.
SPEQ’s shared five-stage progression, labelled synthesis — not the FDA QMM rating scale. Where does your organization sit? Score your quality system →
07 · REGULATORY & EVIDENCE
GOVERNING STANDARDS · 3
Derived from the 3 standards SPEQ maps to this subject, across 3 regulatory bodies: EMA, FDA, ICH.
RECORDS & OBJECTIVE EVIDENCE
- A documented search strategy naming substances, terms, databases, and logic
- Screening-frequency records demonstrating the defined cadence was met
- An auditable trail from each relevant article to the reported ICSR
- Mapping of the portfolio against the EMA Medical Literature Monitoring list
- Vendor-oversight records where literature monitoring is delegated
COMMON INSPECTION FINDINGS
- No documented literature search strategy or defined frequency
- A serious published case not identified within its reporting clock
- Substances double-reported that the EMA MLM service already captures
- Search scope leaving a mandated safety source unwatched
- Delegated literature monitoring without holder oversight or QPPV accountability
Why the literature is a mandated safety source
Pharmacovigilance obligations require the authorisation holder to monitor all sources of safety information about its medicines, and the scientific literature is explicitly one of them. The reason is simple: adverse reactions, drug interactions, and safety observations are frequently first published in journals — a clinician who sees an unusual reaction may write it up before it ever reaches a spontaneous-reporting system. A published case describing an identifiable patient, a suspect medicine, and an adverse event meets the criteria for a valid ICSR, and the holder is responsible for finding it, assessing it, and reporting it on the same clocks as any other case.
This makes literature monitoring a genuine pharmacovigilance duty with reporting consequences, not a research nicety. Missing a serious, unexpected case published in a monitored journal is the same compliance failure as missing one reported directly — the obligation is to *have found it*. That is why literature monitoring is a defined, documented, and auditable process rather than an informal habit: an inspection will ask to see the search strategy, the databases, the frequency, and the trail from article to reported case.
A systematic, documented search — not an occasional look
A compliant literature-monitoring process has defined components. It searches **specified databases** (the major biomedical literature databases) using a **documented search strategy** — the active substances, the search terms, and the logic — that is broad enough to catch relevant safety information without drowning in irrelevance. It runs on a **defined frequency**: because serious cases carry expedited reporting clocks that start when the holder could reasonably have been aware, literature is typically screened at least **weekly** for products where that cadence is needed, so a serious case in a just-published article is caught in time to meet its deadline.
The workflow then runs from search to reportable output: articles are screened for relevance, relevant ones are reviewed in full, valid ICSRs are extracted and processed like any other case (with the article as the source document), and safety information that is not an individual case still feeds signal detection and periodic reporting. The whole chain is documented — what was searched, what was found, what was excluded and why, and what was reported — because the auditable trail *is* the evidence that the obligation was met. A gap in the search strategy or a lapsed frequency is a pharmacovigilance finding regardless of whether a case was actually missed.
The EMA Medical Literature Monitoring service
A wrinkle worth understanding in the EU is that the EMA runs a centralised **Medical Literature Monitoring (MLM)** service for a defined list of active substances and herbal substances: the Agency itself monitors specified literature, identifies suspected adverse-reaction reports, and enters the resulting ICSRs into EudraVigilance. For substances covered by the MLM service, marketing-authorisation holders are relieved of the duty to monitor that same literature for those substances and to submit those cases — precisely to avoid duplicate reporting of the same published case by many holders.
The practical point is that a holder’s literature-monitoring scope is *defined against* the MLM list: it must monitor the literature for its substances **except** where the MLM service covers them, and it must not double-report cases the EMA is already capturing. Getting this boundary wrong in either direction is an error — monitoring a substance the MLM already covers wastes effort and risks duplicate ICSRs, while assuming MLM coverage that does not exist leaves a genuine gap in a mandated safety source. Knowing exactly which of your substances are on the MLM list, and keeping that mapping current, is part of running literature monitoring correctly.
Literature monitoring in the pharmacovigilance system
Literature monitoring is one input among several into the same pharmacovigilance machinery: the ICSRs it produces flow into case processing and expedited reporting on the standard clocks, the non-case safety information it surfaces feeds signal detection, and its cumulative findings are summarised in periodic safety reports. It is described in the pharmacovigilance system master file and owned, like the rest of the system, under the accountability of the QPPV, and it can be delegated to a vendor as a task while the responsibility stays with the holder.
The reason it deserves its own discipline is that it is easy to under-resource and hard to fake: a thin or lapsed literature search leaves a mandated safety source unwatched, and the failure is invisible until an inspection reconstructs what should have been found. A pharmacovigilance system that has strong spontaneous-report handling but a weak literature process has a blind spot exactly where new safety signals often first appear — in print, before they reach a reporting form.
FREQUENTLY ASKED
Why must companies monitor the scientific literature for safety information?
Because pharmacovigilance obligations require monitoring all sources of safety information, and the literature is explicitly one of them. Adverse reactions are frequently first published in journals, and a published case with an identifiable patient, a suspect medicine, and an adverse event is a valid individual case safety report (ICSR). The holder must find it, assess it, and report it on the same clocks as any other case — missing one is the same failure as missing a directly reported case.
How often does literature need to be screened?
On a defined frequency, typically at least weekly where serious cases are possible, because expedited reporting clocks start when the holder could reasonably have been aware. A compliant process uses specified databases and a documented search strategy (active substances, terms, logic), and keeps an auditable trail from article to reported case. A lapsed frequency or a gap in the search strategy is a finding regardless of whether a case was actually missed.
What is the EMA Medical Literature Monitoring (MLM) service?
A centralised EMA service that monitors specified literature for a defined list of active and herbal substances, identifies suspected adverse-reaction reports, and enters the resulting ICSRs into EudraVigilance. For substances it covers, marketing-authorisation holders are relieved of monitoring that literature and submitting those cases — avoiding duplicate reporting. A holder must monitor its substances except where the MLM covers them, so knowing which substances are on the MLM list is essential.
Can literature monitoring be outsourced?
The task can be delegated to a vendor, but the responsibility stays with the marketing-authorisation holder under the QPPV’s accountability, and the process is described in the pharmacovigilance system master file. A weak or lapsed literature process leaves a mandated safety source unwatched — a blind spot exactly where new signals often first appear, in print, before they reach a reporting form.